Want to see TSE:MDP full AI Analyst Report?
Total Valuation
Medexus Pharmaceuticals Inc has a market cap or net worth of C$158.70M. The enterprise value is C$192.00.
Market CapC$158.70M
Enterprise ValueC$192.00
Share Statistics
Medexus Pharmaceuticals Inc has 31,425,983 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31,425,983
Owned by Insiders8.49%
Owned by Institutions0.03%
Financial Efficiency
Medexus Pharmaceuticals Inc’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is 6.08%.
Return on Equity (ROE)-0.05
Return on Assets (ROA)-0.02
Return on Invested Capital (ROIC)6.08%
Return on Capital Employed (ROCE)0.06
Revenue Per Employee1.10M
Profits Per Employee-26.60K
Employee Count90
Asset Turnover0.67
Inventory Turnover1.35
Valuation Ratios
The current PE Ratio of Medexus Pharmaceuticals Inc is ―. Medexus Pharmaceuticals Inc’s PEG ratio is 0.25.
PE Ratio―
PS Ratio1.02
PB Ratio2.06
Price to Fair Value2.06
Price to FCF27.10
Price to Operating Cash Flow8.30
PEG Ratio0.25
Income Statement
In the last 12 months, Medexus Pharmaceuticals Inc had revenue of 99.33M and earned -2.39M in profits. Earnings per share was -0.07.
Revenue99.33M
Gross Profit54.41M
Operating Income5.83M
Pretax Income-2.27M
Net Income-2.39M
EBITDA12.66M
Earnings Per Share (EPS)-0.07
Cash Flow
In the last 12 months, operating cash flow was 13.84M and capital expenditures -15.05M, giving a free cash flow of -1.21M billion.
Operating Cash Flow13.84M
Free Cash Flow-1.21M
Free Cash Flow per Share-0.04
Dividends & Yields
Medexus Pharmaceuticals Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.10
52-Week Price Change68.90%
50-Day Moving Average5.09
200-Day Moving Average3.84
Relative Strength Index (RSI)49.08
Average Volume (3m)45.62K
Important Dates
Medexus Pharmaceuticals Inc upcoming earnings date is Nov 11, 2026, Before Open (Confirmed).
Last Earnings DateAug 10, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Medexus Pharmaceuticals Inc as a current ratio of 1.19, with Debt / Equity ratio of 54.62%
Current Ratio1.19
Quick Ratio0.57
Debt to Market Cap0.22
Net Debt to EBITDA1.24
Interest Coverage Ratio1.12
Taxes
In the past 12 months, Medexus Pharmaceuticals Inc has paid 120.00K in taxes.
Income Tax120.00K
Effective Tax Rate-0.05
Enterprise Valuation
Medexus Pharmaceuticals Inc EV to EBITDA ratio is 9.21, with an EV/FCF ratio of 31.34.
EV to Sales1.17
EV to EBITDA9.21
EV to Free Cash Flow31.34
EV to Operating Cash Flow6.18
Balance Sheet
Medexus Pharmaceuticals Inc has C$5.34M in cash and marketable securities with C$26.21M in debt, giving a net cash position of -C$20.88M billion.
Cash & Marketable SecuritiesC$5.34M
Total DebtC$26.21M
Net Cash-C$20.88M
Net Cash Per Share-C$0.66
Tangible Book Value Per Share-C$0.73
Margins
Gross margin is 54.73%, with operating margin of 5.87%, and net profit margin of -2.41%.
Gross Margin54.73%
Operating Margin5.87%
Pretax Margin-2.29%
Net Profit Margin-2.41%
EBITDA Margin12.75%
EBIT Margin2.95%
Analyst Forecast
The average price target for Medexus Pharmaceuticals Inc is C$6.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$6.50
Price Target Upside28.46% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-3.16%
EPS Growth Forecast-345.50%